Sarepta Therapeutics | SRPT

Peers Price Chg Day Year Date
4568 Daiichi Sankyo 5,003.00 239.00 5.02% 6.22% Apr/26
ACAD Acadia Pharmaceuticals 16.32 -0.27 -1.63% -19.65% Apr/25
AGIO Agios Pharmaceuticals 31.67 0 0% 43.30% Apr/25
ALNY Alnylam Pharmaceuticals 143.70 -0.09 -0.06% -27.25% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
AVRO Avrobio 1.18 -0.02 -1.26% 32.58% Apr/25
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
INCY Incyte 51.16 -0.62 -1.20% -30.43% Apr/25
INSM Insmed 24.93 -0.88 -3.41% 28.77% Apr/25
IONS Ionis Pharmaceuticals 41.81 -0.65 -1.53% 16.95% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MRNA Moderna 106.22 -2.79 -2.56% -18.75% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PTCT PTC Therapeutics 25.49 0.28 1.11% -51.21% Apr/25
RARE Ultragenyx Pharmaceutical 43.85 -0.41 -0.93% 3.59% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
ROG Roche Holding 219.30 0.50 0.23% -20.60% Apr/26
SAN Sanofi 89.69 -1.94 -2.11% -11.92% Apr/26
SRPT Sarepta Therapeutics 127.41 3.16 2.54% 4.20% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
RTY US2000 1981 -14.31 -0.72% 13.13% Apr/26

Sarepta Therapeutics traded at $127.41 this Thursday April 25th, increasing $3.16 or 2.54 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics gained 0.66 percent. Over the last 12 months, its price rose by 4.20 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 126.99 by the end of this quarter and at 119.85 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.